Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Navigating Payer Denials: A Physician Advisor’s Perspective #1

America’s healthcare system is buckling under a contradiction we’ve normalized: we expect reliable care for roughly 380 million people while letting every major lever of the system be pulled by for-profit players chasing the same dollar. In any market, companies will optimize for profit, but in medicine that instinct collides with a rulebook…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Payerwatch · Cms RegulationFor-profit HealthcareHealthcareHealthcare Policy
Share

Key takeaways

01

America’s healthcare system is buckling under a contradiction we’ve normalized: we expect reliable care for roughly 380 million people while letting every major lever of the system be pulled by for-profit players chasing the same dollar.

02

In any market, companies will optimize for profit, but in medicine that instinct collides with a rulebook…

America’s healthcare system is buckling under a contradiction we’ve normalized: we expect reliable care for roughly 380 million people while letting every major lever of the system be pulled by for-profit players chasing the same dollar. In any market, companies will optimize for profit, but in medicine that instinct collides with a rulebook so sprawling and murky—think the endless chess match between “observation” and “inpatient” status—that fairness becomes more myth than mechanism.

The result is a landscape where savvy institutions can game classifications and loopholes to thrive financially, even when patients are left confused, delayed, or stuck with bills they never saw coming. That’s why the call for CMS to step in with clearer, firmer standards matters: not because government is magically wiser, but because a fragmented profit race has proven incapable of policing itself. Still, even a stronger referee won’t fix the deeper question hovering over all this—what are we willing to sacrifice to keep healthcare a business first?

If the answer is that most Americans must struggle so a few entities can flourish, then the “rules” aren’t the real problem; the entire concept needs a hard reset.

About the author

P
Payerwatch

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The Future of Healthcare Is Already Here: Dr. Geoffrey Rutledge on Virtual Care, AI, and Access

The Future of Healthcare Is Already Here: Dr. Geoffrey Rutledge on Virtual Care, AI, and Access

The article discusses the advancements in healthcare with a focus on virtual care, AI, and access, featuring insights from Dr. Geoffrey Rutledge. It explores how these technologies are shaping the future of healthcare delivery. The conversation touches upon the impact on patient care and the potential for improved healthcare accessibility.

  • 01Virtual care and AI are transforming healthcare.
  • 02These technologies enhance patient accessibility and care.
  • 03Healthcare delivery is continuously evolving with new innovations.

Jul 14, 2026

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

P
Payerwatch

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512